Oncology January 2011
Epigenetic Agents for the Treatment of Hematologic Malignancies
Four epigenetic agents (vorinostat, romidepsin, azacitidine,
decitabine) have been approved by the FDA for the treatment of
hematologic malignancies.
Typical Drug Interactions in Oncology
Precise data are not available, but the occurrence of drug-drug
interactions in oncology is theorized to be higher than in most other
conditions.
Continuing Education
$7.95 Per CE Exam or $69 for 12 Lessons
-
• April 2026 • 2.00 Credits
Managing HIV Coinfections and Complications
-
Pain Management • March 2026 • 2.00 Credits
Updated Guidance for Opioid Use in Pain Management
-
Cardiovascular • February 2026 • 2.00 Credits
Managing Modifiable Risk Factors in Chronic Coronary Disease
Copyright © 2000 - 2024 Jobson Medical Information LLC unless otherwise noted. All rights reserved. Reproduction in whole or in part without permission is prohibited.